Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous dendritic cell + autologous tumor cell antigens vaccine
- Development stage
- Unknown
- Lead developer
- Aivita Biomedical
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
Autologous dendritic cell + autologous tumor cell antigens vaccine (DC-ATA) is a personalized, cell-based cancer immunotherapy developed by AIVITA Biomedical. The vaccine is produced by isolating a patient's own dendritic cells and loading them ex vivo with antigens derived from the patient's own tumor-initiating (stem-like) cells, which are expanded in culture. The resulting product is suspended in granulocyte-macrophage colony-stimulating factor (GM-CSF) and administered via subcutaneous injection. This approach is designed to prime the patient's immune system, specifically T lymphocytes, to recognize and eliminate cancer stem cells that are typically resistant to standard chemotherapy and radiation. The platform has been investigated in clinical trials for various solid tumors, including glioblastoma (AV-GBM-1), metastatic melanoma (AV-MEL-1), ovarian cancer (AV-OV-2), and hepatocellular carcinoma (AV-HCC-1).
- Other names
- autologous dendritic cell/autologous tumor cell antigensROOTS
02
Targets
CD28 (Cluster of Differentiation 28)CD40 (Cluster of differentiation 40 receptor)
Beyond the preview
Go deeper on autologous dendritic cell + autologous tumor cell antigens vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous dendritic cell + autologous tumor cell antigens vaccine.